Changwen Li

Title: Changwen Li: Innovator in Pharmaceutical Chemistry

Introduction

Changwen Li is a notable inventor based in Tianjin, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative drug formulations. With a total of 2 patents, his work has the potential to impact various therapeutic areas.

Latest Patents

Changwen Li's latest patents include a crystalline form of ethyl (S)-3-(8-bromo-1-methyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,2-a][1,4]diazepin-4-yl)propanoate hydrochloride. This invention provides a crystalline form of a benzodiazepine derivative hydrochloride, along with a method for preparing this crystal form and a pharmaceutical composition that includes it. Another significant patent involves a pharmaceutical composition containing silibinin and pueraria root extract, aimed at treating non-alcoholic fatty liver. This composition is prepared from a specific weight ratio of silibinin, phospholipid, Pu'er tea extract, and radix puerariae extract.

Career Highlights

Throughout his career, Changwen Li has worked with prominent companies in the pharmaceutical industry. He has been associated with Jiangsu Nhwaluokang Pharmaceutical Research and Development Co., Ltd. and Tasly Pharmaceutical Group Co., Ltd. His experience in these organizations has contributed to his expertise in drug development and formulation.

Collaborations

Changwen Li has collaborated with several professionals in his field, including Qingeng Li and Chen Duan. These collaborations have likely enhanced his research and development efforts, leading to innovative solutions in pharmaceutical chemistry.

Conclusion

Changwen Li's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an innovator in the industry. His work continues to pave the way for advancements in drug formulations and therapeutic applications.